CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 62 enrolled
Drug / intervention
Levocetirizinedrug
Likely dose
Levocetirizine 5 mg orally once dailyAI-extracted
Key inclusion· 3
  • ✓Clinical history of persistent allergic rhinitis (PER) requiring treatment for at least 2 years
  • ✓Positive skin prick test (wheal >3 mm larger than control) or RAST (≥3.5 IU/ml) to house dust mite and parietaria within the last year
  • ✓Minimum mean Total 4 Symptom Score (T4SS) of 6 or higher at baseline
Key exclusion· 5
  • ✕Currently receiving specific parietaria pollen immunotherapy
  • ✕Non-allergic asthma
  • ✕Chronic use of inhaled steroids and/or long-acting β2 agonists
  • ✕Corticosteroid-dependent asthma (severe asthma)

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00160680
NCT00160680Phase 4Completed
CompareCT.gov

A Pilot, Open, Monocenter, Randomized Two Parallel Groups, Clinical Efficacy Trial: Comparison Continuous Versus on Demand Regimen of Treatment With Levocetirizine 5 mg Oral Tablets, Once a Day, in Adults Suffering From Persistent Allergic Rhinitis (PER) Over 6 Months

UCB S.A. - Pharma Sector·interventional·Posted Sep 12, 2005·Updated Aug 31, 2023

In Brief

A Phase 4 clinical trial evaluating Levocetirizine for Rhinitis, Allergic, Perennial. Completed, enrolled 62 participants across 1 site.

Detailed Summary

Comparison of clinical efficacy and safety of levocetirizine in PER continuous versus on demand, measured by evolution of individual symptom scores during 6 months.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRhinitis, Allergic, Perennial
CountriesItaly
Collaborators--

Timeline

Phase 4CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedSep 12, 2005
Enrollment StartMar 1, 2005
Primary CompletionJun 1, 2006
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 20.8 years ago

Interventions

Levocetirizinedrug

* Pharmaceutical form: Tablet * Concentration: 5 mg * Route of administration: Oral use